Tachykinin upregulation in atopic dermatitis

Lönndahl, Louise; Rasul, Aram; Lonne-Rahm, Sol-Britt; Holst, Mikael; Johansson, Björn; El-Nour, Husameldin; Djurfeldt, Diana Radu; Nordlind, Klas

doi:10.1080/08923973.2018.1558235

Cited by 12 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In biopsies from lesional skin of AD patients, they found an increase in the number of SP-and NKA-positive nerve fibres and NKA-positive mononuclear dermal cells, compared to non-lesional skin. Moreover, the depression score and the number of dermal NK1R-positive cells in lesional and non-lesional skin showed a positive correlation [63].…”

Section: Atopic Dermatitismentioning

confidence: 83%

“…A subsequent study by the group investigated the expression of tachykinin markers in AD skin and whether they correlate with clinical and psycho-demographic parameters [63]. In biopsies from lesional skin of AD patients, they found an increase in the number of SP-and NKA-positive nerve fibres and NKA-positive mononuclear dermal cells, compared to non-lesional skin.…”

Section: Atopic Dermatitismentioning

confidence: 99%

See 1 more Smart Citation

Neurokinin 1 Receptor Antagonists for Pruritus

Alam

Buddenkotte

Faried

et al. 2021

Drugs

View full text Add to dashboard Cite

Pruritus, commonly known as itch, is a very common symptom in numerous dermatological disorders and systemic diseases. It can manifest as acute, or when lasting longer than 6 weeks, it is considered chronic and can lead to significant distress and reduced quality-of-life of those suffering. Current therapeutics are limited and are lacking in efficacy, and the development of more effective treatments is needed. The neurokinin 1 receptor (NK1R) antagonists are a novel class of drugs that possess several properties such as antidepressant, anxiolytic and antiemetic activities. Recently, several studies have described the antipruritic activity of NK1R antagonists for treating chronic pruritus. In this review we outline the pathogenesis of chronic pruritus, the mechanism by which the neuropeptide substance P (SP) and its receptor NK1R may be targeted to inhibit pruritic activity, and the efficacy and tolerability of NK1R antagonists, which have been, or are currently being investigated for treating conditions where chronic pruritus is a major symptom. Increasing evidence from ongoing and completed studies demonstrates the importance of SP and NK1R signalling in mediating pruritic activity. Several NK1R antagonists have shown significant antipruritic activity and thus targeting the SP-NK1R pathway may provide a therapeutic option for treating chronic pruritus of certain origin/s in the foreseeable future.

show abstract

Section: Atopic Dermatitismentioning

confidence: 83%

Section: Atopic Dermatitismentioning

confidence: 99%

Neurokinin 1 Receptor Antagonists for Pruritus

Alam

Buddenkotte

Faried

et al. 2021

Drugs

View full text Add to dashboard Cite

show abstract

“…Studies also found that the increase of substance P is due to the upregulation of the tachykinesia system in the skin of patients with inflammatory atopic dermatitis. 15 Pruritus is a significant symptom of AD. Studies investigating the mechanisms of pruritus in humans and mice have reported substance P to be an important mediator of this symptom.…”

Section: Discussionmentioning

confidence: 99%

Susbstance P Levels in Children with Atopic Dermatitis

Nasution

Paramita

Lubis

2021

BIKK

View full text Add to dashboard Cite

Background: Atopic dermatitis (AD) is the most common skin disease in infants and children. AD is influenced by hereditary and environmental factors, and it is characterized by an inflammatory reaction in the skin. In developing countries, children suffering from AD are estimated around 10–20%, of which 60% of the cases persist into adulthood. Substance P is a cutaneous neuropeptide that contributes to the pathogenesis of AD. Substance P promotes the production of nerve growth factors from keratinocytes, and the release of histamine, leukotriene, or tumor necrosis factor from mast cells, which cause the growth of sensory nerve fibers, augmentation of skin inflammation, and are considered pruritogenic factors. Purpose: This study aims to determine the description of substance P in children with atopic dermatitis using a descriptive observational study with a cross-sectional approach. Methods: This is a destructive observational study with a crossectional approach samples were selected from AD patients at the Universitas Sumatera Utara Hospital. Result: The largest group of subjects were childhood (2–12 years old), there was 60%, followed by the adolescent group (12–18 years old) and the infant group (<2 years old). In the childhood group, the highest level of substance P was found in girls with a mean of 349.03 ± 146.7. On the other hand, the highest levels of substance P in the adolescent were found in males with a mean of 243.73 ± 64.57 ng/L. Conclusion: In this study, we found that the level of substance p was higher in the childhood group.

show abstract

“…In addition to NK1R, SP can bind to Mas-related G protein-coupled receptors (MRGPCRs), which are implicated in nociception and itch signaling [140]. Increases in SP expression in serum and lesioned skin and NK1R+ fibers in lesioned skin in patients with AD have been reported [141]. However, a recent study revealed no significant relationship between serum SP levels and AD [142].…”

Section: Neuropeptidesmentioning

confidence: 99%

The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis

Wong

Yen

Lee

2021

IJMS

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a prototypic inflammatory disease that presents with intense itching. The pathophysiology of AD is multifactorial, involving environmental factors, genetic susceptibility, skin barrier function, and immune responses. A recent understanding of pruritus transmission provides more information about the role of pruritogens in the pathogenesis of AD. There is evidence that pruritogens are not only responsible for eliciting pruritus, but also interact with immune cells and act as inflammatory mediators, which exacerbate the severity of AD. In this review, we discuss the interaction between pruritogens and inflammatory molecules and summarize the targeted therapies for AD.

show abstract

Tachykinin upregulation in atopic dermatitis

Cited by 12 publications

References 37 publications

Neurokinin 1 Receptor Antagonists for Pruritus

Neurokinin 1 Receptor Antagonists for Pruritus

Susbstance P Levels in Children with Atopic Dermatitis

The Implications of Pruritogens in the Pathogenesis of Atopic Dermatitis

Contact Info

Product

Resources

About